Information Provided By:
Fly News Breaks for November 30, 2016
ARWR
Nov 30, 2016 | 07:17 EDT
As noted earlier, Cantor downgraded Arrowhead to Hold from Buy. Analyst Elemer Piros downgraded the stock after the company announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT but pursuing its subcutaneously delivered candidates. The analyst says that the subcutaneously delivered candidates are in early stages of development and lack visibility. Target to $1 from $15.
News For ARWR From the Last 2 Days
There are no results for your query ARWR